CLINICAL STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radiation boost for cancer immunotherapy?
Disease control OngoingThis study is testing if adding a short, precise course of radiation (SBRT) to an immunotherapy drug (pembrolizumab) works better than the drug alone for people with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. It aims to see if the combination helps control…
Matched conditions: CLINICAL STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Balancing act: fighting cancer while protecting a transplanted kidney
Disease control OngoingThis early-phase study is testing a combination of immunotherapy drugs (nivolumab and ipilimumab) along with standard transplant medications (tacrolimus and prednisone) in kidney transplant patients with advanced skin cancers that have spread or cannot be removed by surgery. The …
Matched conditions: CLINICAL STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug combo tested for Tough-to-Treat skin cancer
Disease control OngoingThis study is for people with advanced Merkel cell carcinoma, a rare and aggressive skin cancer, that has worsened despite prior immunotherapy. It is testing whether a new oral drug called tuvusertib, which targets cancer cell DNA repair, works better alone or when combined with …
Matched conditions: CLINICAL STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC